Are insurance companies following CCSVI developments? I know Big Pharma is and they don't like it!
my turn to ask a question.....does anyone have direct quotes from big pharma
about their stand on ccsvi?
Don't think pharma will directly do big quotes (they cannot admit) but they find their ways to sneak them in via other routes or action... For example the news on Fingolimod was greatly placed in the Italian RAI media news everywhere on TV just before an important Zamboni conference in Italy. No question it undermined CCSVI news, as when I asked that w-end of the conference friends and family whether they have heard of the media news on MS and CCSVI they all said "ah yes, I heard about that - yesterday saw news about this new promising pill that cures MS!"
So who knows how much anti-CCSVI pharma lobby "gift" cash for such strategies flows behind the curtains to govs/media, doctors/scientific pubs, (associations?), and other...
To approach private insurance companies would think is good idea, as they would have a purer economic interest. However, not each country is based on private insurance company systems in same weight. And although the gov's healh care systems should realise that there is loads of money to save, the politics on also other economic interests such as pharma then come into play. Well, I guess we all know this.
And wonder if anyone will find a direct anti-CCSVI pharma quote...
However, found this link, which is interesting:
http://csvi-ms.net/en/content/critical- ... -neurology
An Open Letter to the Authors of Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis (Khan et al, 2010, Annals of Neurology) Ashton Embry, Direct-MS
Background: A week ago a “Point of View” article on Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis was made available online at the website of Annals of Neurology. It was written by 11 authors, with both neurologists and radiologists being represented. Notably 7 of 11 authors (including the first four, senior authors) disclosed significant financial interests with pharmaceutical companies which produce drugs for MS (see Appendix)...